Norris Medicines

Which are the latest news on Norris Medicines?

Are Norris Medicines Ltd latest results good or bad?

Norris Medicines Ltd's latest results show a net profit of ₹0.05 crores, a positive shift from last year's loss, but a concerning 48.16% decline in revenue raises doubts about its market stability and financial health. Overall, while profitability has improved, significant challenges remain.

The latest results for Norris Medicines Ltd present a mixed picture. On one hand, the company achieved a net profit of ₹0.05 crores in Q4 FY26, a significant improvement from a loss of ₹0.23 crores in the same quarter last year. This indicates a positive shift in profitability.<BR><BR>However, this positive development is overshadowed by a dramatic decline in revenue, which fell by 48.16% year-on-year and 56.88% sequentially from the previous quarter, resulting in net sales of just ₹1.41 crores. Such a steep drop raises concerns about the company's market position and operational stability.<BR><BR>Additionally, while the operating margin improved to 21.99% from 2.57% a year earlier, it decreased from 29.05% in the previous quarter, highlighting volatility in performance. The company also operates with a negative book value, indicating significant financial distress and accumulated losses.<BR><BR>In summary, while Norris Medicines has made strides in profitability, the severe revenue decline and underlying financial challenges suggest that the overall results are concerning. The company faces significant hurdles in achieving sustainable growth and stability moving forward.

Should I buy, sell or hold Norris Medicines Ltd?

When is the next results date for Norris Medicines Ltd?

The next results date for Norris Medicines Ltd is 30 May 2026.

The next results date for Norris Medicines Ltd is scheduled for 30 May 2026.

How has been the historical performance of Norris Medicines?

Norris Medicines has shown a declining trend in net sales and profitability, with net sales dropping from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25, and consistent losses reported, including a profit after tax of -1.24 Cr in Mar'25. The company's financial distress is further highlighted by a deteriorating book value per share of -14.98 and stagnant cash flow from operating activities.

Answer:<BR>The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Norris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities stood at 12.91 Cr in Mar'25, with total debt slightly increasing to 21.58 Cr. The book value per share has deteriorated to -14.98 in Mar'25, highlighting the company's financial distress. Cash flow from operating activities has been stagnant, with no cash inflow reported in recent years, further emphasizing the company's ongoing struggles.

How big is Norris Medicines?

As of 24th July, Norris Medicines Ltd has a market capitalization of 16.00 Cr and reported Net Sales of 5.82 Cr with a Net Profit loss of 1.24 Cr for the latest four quarters. As of March 2024, Shareholder's Funds were at a loss of 13.63 Cr, while Total Assets were valued at 13.22 Cr.

As of 24th July, Norris Medicines Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 5.82 Cr. However, it experienced a Net Profit loss of 1.24 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds stood at a loss of 13.63 Cr, while Total Assets were valued at 13.22 Cr.

Who are the top shareholders of the Norris Medicines?

The top shareholders of Norris Medicines are Vimal D Shah, the promoter with 23.6%, and Fab Metals Private Limited, the largest public shareholder with 41.99%. Individual investors hold 20.76%, while mutual funds hold a minimal 0.01%, and there are no foreign institutional investors or pledged promoter holdings.

The top shareholders of Norris Medicines include Vimal D Shah, who is the promoter with the highest holding at 23.6%. Additionally, Fab Metals Private Limited is the highest public shareholder, holding 41.99%. Individual investors collectively hold 20.76% of the shares. There are also two mutual fund schemes that hold a very small percentage (0.01%), while there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

Who are the peers of the Norris Medicines?

Norris Medicines' peers include Mihika Industrie, Regent Enterprises, NMS Global, Yash Management & Sat., AA Plus Trade, Shyam Telecom, Muller & Phipps, Dalmia Industria, Sumeru Industrie, and Diggi Multitrade. While Norris Medicines has a 1-year return of 33.84%, its peers generally show below-average management and growth risks, with negative returns for several.

Peers: The peers of Norris Medicines are Mihika Industrie, Regent Enterp., NMS Global, Yash Mgmt & Sat., AA Plus Trade, Shyam Telecom, Muller & Phipps, Dalmia Industria, Sumeru Industrie, and Diggi Multitrade.<BR><BR>Quality Snapshot: Below Average management risk is observed at Mihika Industrie, Regent Enterp., NMS Global, Yash Mgmt & Sat., AA Plus Trade, and Diggi Multitrade, while Average management risk is found at none. Management risk does not qualify for Norris Medicines, Shyam Telecom, Muller & Phipps, Dalmia Industria, and Sumeru Industrie. Average growth is noted at Mihika Industrie, Regent Enterp., Yash Mgmt & Sat., and the rest have Below Average growth, including NMS Global, AA Plus Trade, and Diggi Multitrade. Growth does not qualify for Norris Medicines, Shyam Telecom, Muller & Phipps, Dalmia Industria, and Sumeru Industrie. Excellent capital structure is present at Regent Enterp. and Yash Mgmt & Sat., while Below Average capital structure is seen at Mihika Industrie, NMS Global, AA Plus Trade, and Diggi Multitrade, with the rest not qualifying.<BR><BR>Return Snapshot: NMS Global has the highest 1-year return at -37.96%, while AA Plus Trade has the lowest at -71.95%. Norris Medicines has a 1-year return of 33.84%, which is significantly higher than both. Additionally, peers such as Mihika Industrie, Regent Enterp., AA Plus Trade, and Diggi Multitrade have negative six-month returns.

Why is Norris Medicines falling/rising?

As of 10-Jun, Norris Medicines Ltd is experiencing a price increase to 19.74, reflecting a 2.07% upward change. Despite strong annual returns and positive technical trends, the company faces challenges such as negative book value, high debt levels, and declining sales, indicating potential risks ahead.

As of 10-Jun, Norris Medicines Ltd is experiencing a price increase, currently at 19.74, reflecting a change of 0.4 or 2.07% upward. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive technical trend. Additionally, the stock has outperformed its sector by 1.55% today, and there has been a significant rise in investor participation, with delivery volume increasing by 73.44% compared to the 5-day average. Over the past year, Norris Medicines has generated an impressive return of 71.21%, significantly outperforming the market benchmark, which has only returned 6.22%. However, the company faces challenges, including a negative book value and weak long-term fundamental strength, as evidenced by declining net sales and operating profits over the past five years.<BR><BR>In the broader market context, while Norris Medicines has shown strong performance over the past year, its recent short-term return of -3.00% over the last week contrasts with the Sensex's gain of +2.05%. This divergence suggests that despite the stock's overall bullish trend, it has faced some recent headwinds. The company's high debt levels and negative EBITDA further contribute to its risk profile, indicating that while the stock may be currently rising, underlying financial weaknesses could pose challenges ahead.

Is Norris Medicines overvalued or undervalued?

As of April 25, 2023, Norris Medicines is considered risky and overvalued due to its negative PE ratio of -16.05 and poor financial metrics compared to competitors, despite a recent stock performance that outpaced the Sensex.

As of 25 April 2023, the valuation grade for Norris Medicines has moved from does not qualify to risky, indicating significant concerns regarding its financial health. The company appears to be overvalued, given its negative PE ratio of -16.05, a Price to Book Value of -1.39, and an EV to EBIT of -41.46. These ratios highlight severe profitability and valuation issues compared to its peers.<BR><BR>In comparison to industry competitors, Norris Medicines' metrics starkly contrast with those of Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25, and Cipla Ltd., with a PE ratio of 22.99. The significant disparity in these ratios suggests that Norris Medicines is not only underperforming but also carries a higher risk profile. While the stock has outperformed the Sensex over the past year with a return of 66.24% compared to the Sensex's 7.55%, the underlying financial metrics indicate that the current valuation does not justify this performance, reinforcing the conclusion of being overvalued.

What is the technical trend for Norris Medicines?

As of June 5, 2025, Norris Medicines shows a mildly bullish trend supported by bullish MACD and KST indicators, although daily moving averages indicate caution in the short term.

As of 5 June 2025, the technical trend for Norris Medicines has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supporting the positive shift, while the monthly MACD also confirms this bullish stance. The Bollinger Bands indicate a mildly bullish trend on both weekly and monthly time frames. The KST is mildly bullish weekly and bullish monthly, further reinforcing the upward momentum. However, daily moving averages remain mildly bearish, which suggests caution in the short term. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators.

What does Norris Medicines do?

Norris Medicines Ltd is a micro-cap company in the Trading & Distributors industry, specializing in the manufacture of non-sterile and sterile dosage forms. As of March 2025, it reported net sales of 3 Cr and a market cap of Rs 20 Cr.

Overview:<BR>Norris Medicines Ltd is a micro-cap company in the Trading & Distributors industry, specializing in the manufacture of non-sterile and sterile dosage forms, including tablets, capsules, liquid orals, and injectable ampoules and vials.<BR><BR>History:<BR>Norris Medicines Ltd was established in September 1990 and was converted into a Public Limited Company on March 7, 1992. The company commenced commercial production in November 1991 and has reported net sales and profit for the quarter ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.50<BR>- Return on Equity: 8.64%<BR>- Price to Book: -1.35<BR><BR>Contact Details:<BR>- Address: Plot No 801/P & 802, GIDC Industrial Estate Ankleshwar Gujarat : 393002<BR>- Tel: 91-2646-223462/227530<BR>- Email: secretarial@norrispharma.com<BR>- Website: http://www.norrispharma.com

Who are in the management team of Norris Medicines?

As of March 2022, the management team of Norris Medicines consists of Vimal D Shah as Managing Director and Hiten Parikh, S A M Azmathullah, and Susmita Mahapatra as Independent Directors.

As of March 2022, the management team of Norris Medicines includes the following individuals:<BR><BR>1. Vimal D Shah - Managing Director<BR>2. Hiten Parikh - Independent Director<BR>3. S A M Azmathullah - Independent Director<BR>4. Susmita Mahapatra - Independent Director<BR><BR>Vimal D Shah is the Managing Director, while the other three members serve as independent directors.

Has Norris Medicines declared dividend?

No Dividend History Available